Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmented behavior therapy for tic disorders
NCT04357951Phase 1Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial in Tourette syndrome (TS) and tic disorders comparing Behavior Therapy + DCS with Behavior Therapy + Placebo (2 arms). Primary endpoint: Change in Hopkins Motor/Vocal Tic Scale score. Planned start Apr 2023; status: withdrawn.
02
Drugs
d-cycloserine
03
Conditions
Tourette syndrome (TS)tic disorders
Beyond the preview
Go deeper on NCT04357951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357951.